

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	("5464758").PN.	US-PGPU B; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/08 12:28
L2	1426	Estrogen receptor?	US-PGPU B; USPAT; EPO; JPO	ADJ	ON	2004/12/08 12:29
L3	27	L2 AND single nucleotide polymorphism?	US-PGPU B; USPAT; EPO; JPO	ADJ	ON	2004/12/08 12:29

	Title	Current OR	Current XRef
20	Gene sequence variances in genes related to folate metabolism having utility in determining the treatment of disease	514/1	435/6
21	Pin1 as a marker for abnormal cell growth	435/6	435/7.23
22	Microarray methods utilizing semiconductor nanocrystals	435/6	435/7.92
23	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium	514/179	514/182
24	Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing	435/6	702/20
25	Estrogen receptor beta variants and methods of detection thereof	536/24.3	435/6; 435/91.2; 536/23.5; 536/24.31; 536/25.32
26	Tumor necrosis factor receptor 2	536/22.1	435/6; 435/91.1; 435/91.2; 536/23.1; 536/24.3; 536/24.31; 536/24.33
27	Colon cancer marker	435/69.1	435/320.1; 435/325; 435/70.1; 536/23.1; 536/23.5

	Title	Current OR	Current XRef
1	Neurotransmission-associated proteins	435/6	435/320.1; 435/325; 435/69.1; 530/350; 536/23.5
2	ESTROGEN RECEPTOR BETA VARIANTS AND METHODS OF DETECTION THEREOF	435/6	435/320.1; 435/325; 435/69.1; 530/350; 536/23.5
3	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium	514/170	
4	Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing	435/6	530/350; 536/24.3
5	Nucleic acid-associated proteins	435/6	435/199; 435/320.1; 435/325; 435/69.1; 536/23.2
6	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium	514/170	514/406
7	Secreted proteins	514/12	435/320.1; 435/325; 435/6; 435/69.1; 530/350; 536/23.5
8	Drug metabolizing enzymes	435/6	435/183; 435/320.1; 435/325; 435/69.1; 530/388.26; 536/23.2

	Title	Current OR	Current XRef
9	Proteases	435/6	435/226; 435/320.1; 435/325; 435/69.1; 530/388.26; 536/23.2
10	Proteins and nucleic acids encoding same	435/6	435/183; 435/320.1; 435/325; 435/69.1; 536/23.2
11	Genetic analysis for stratification of cancer risk	435/6	435/287.2
12	Interactions between AR, ER, TR2, and TR4	435/7.1	514/12
13	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer	435/6	435/7.23
14	Methods of treating and preventing bone loss	435/4	435/6; 514/102; 514/12; 514/182
15	Diagnostic markers for breast cancer	435/6	435/91.2; 536/23.2
16	Pin1 as a marker for abnormal cell growth	435/6	435/7.23
17	Novel nuclear receptor corepressor molecules and uses therefor	435/6	435/320.1; 435/325; 435/69.1; 530/358; 536/23.5
18	Estrogen receptor alpha variants and methods of detection thereof	435/69.1	435/320.1; 435/325; 530/350; 530/388.22; 536/23.5
19	Combination therapy for the treatment of estrogen-sensitive disease	435/7.23	514/171; 514/651